Peter Albers1, Walter Albrecht2, Ferran Algaba3, Carsten Bokemeyer4, Gabriella Cohn-Cedermark5, Karim Fizazi6, Alan Horwich7, Maria Pilar Laguna8, Nicola Nicolai9, Jan Oldenburg10. 1. Department of Urology, Medical Faculty, Düsseldorf University, Düsseldorf, Germany. Electronic address: urologie@uni-duesseldorf.de. 2. Department of Urology, Mistelbach, Austria. 3. Department of Pathology, Fundacio Puigvert, Barcelona, Spain. 4. Department of Oncology, Hematology and Bone Marrow Transplantation with section Pneumology, Universitätskliniken Eppendorf, Hamburg, Germany. 5. Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden. 6. Department of Medicine, University of Paris XI, Villejuif, France. 7. Academic Unit of Radiotherapy and Oncology, Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, UK. 8. Department of Urology, Amsterdam Medical Centre, Amsterdam University, Amsterdam, The Netherlands. 9. Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 10. Health Sciences, Høgskolen i Buskerud og Vestfold, Kongsberg, Norway.
Abstract
CONTEXT: This is an update of the previous European Association of Urology testis cancer guidelines published in 2011, which included major changes in the diagnosis and treatment of germ cell tumours. OBJECTIVE: To summarise latest developments in the treatment of this rare disease. Recommendations have been agreed within a multidisciplinary working group consisting of urologists, medical oncologists, and radiation oncologists. EVIDENCE ACQUISITION: A semi-structured literature search up to February 2015 was performed to update the recommendations. In addition, this document was subjected to double-blind peer review before publication. EVIDENCE SYNTHESIS: This publication focuses on the most important changes in treatment recommendations for clinical stage I disease and the updated recommendations for follow-up. CONCLUSIONS: Most changes in the recommendations will lead to an overall reduction in treatment burden for patients with germ cell tumours. In advanced stages, treatment intensification is clearly defined to further improve overall survival rates. PATIENT SUMMARY: This is an update of a previously published version of the European Association of Urology guidelines for testis cancer, and includes new recommendations for clinical stage I disease and revision of the follow-up recommendations. Patients should be fully informed of all the treatment options available to them.
CONTEXT: This is an update of the previous European Association of Urology testis cancer guidelines published in 2011, which included major changes in the diagnosis and treatment of germ cell tumours. OBJECTIVE: To summarise latest developments in the treatment of this rare disease. Recommendations have been agreed within a multidisciplinary working group consisting of urologists, medical oncologists, and radiation oncologists. EVIDENCE ACQUISITION: A semi-structured literature search up to February 2015 was performed to update the recommendations. In addition, this document was subjected to double-blind peer review before publication. EVIDENCE SYNTHESIS: This publication focuses on the most important changes in treatment recommendations for clinical stage I disease and the updated recommendations for follow-up. CONCLUSIONS: Most changes in the recommendations will lead to an overall reduction in treatment burden for patients with germ cell tumours. In advanced stages, treatment intensification is clearly defined to further improve overall survival rates. PATIENT SUMMARY: This is an update of a previously published version of the European Association of Urology guidelines for testis cancer, and includes new recommendations for clinical stage I disease and revision of the follow-up recommendations. Patients should be fully informed of all the treatment options available to them.
Authors: Pia Paffenholz; Johannes Salem; Hendrik Borgmann; Tim Nestler; David Pfister; Christian Ruf; Igor Tsaur; Axel Haferkamp; Axel Heidenreich Journal: J Cancer Educ Date: 2018-12 Impact factor: 2.037
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Elio Mazzone; Sophie Knipper; Francesco A Mistretta; Zhe Tian; Carlotta Palumbo; Denis Soulieres; Ottavio De Cobelli; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2019-08-28 Impact factor: 4.226